1 2 3 262
Number of results: 5229

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2019-08-06 Genprex (USA - TX) Aldevron (USA -MA) TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA manufacturing - production Cancer - Oncology - Technology - Services Production agreement
2019-07-31 RegenXBio (USA - MD) Pfizer (USA - NY) NAV AAV9 vector Friedreich's ataxia licensing Rare diseases - Genetic diseases - Neurodegenerative diseases Licensing agreement
2019-07-30 Alnylam Therapeutics (USA - MA) GENESIS Pharma (Cyprus) Onpattro® transthyretin (TTR)-familial amyloid polyneuropathy (FAP) hereditary transthyretin-mediated amyloidosis (hATTR) commercialisation Rare diseases - Genetic diseases Commercialisation agreement
2019-07-24 RegenXBio (USA - MD) Neurimmune (Switzerland)
  • AAV gene therapies using NAV Vectors to deliver human antibodies against targets implicated in chronic neurodegenerative diseases, including tauopathies.
chronic neurodegenerative diseases, including tauopathies development - licensing Neurodegenerative diseases Development agreement
2019-07-16 Catalent Biologics (USA - NJ) Avexis;,a Novartis company (Switzerland) Zolgensma® (onasemnogene abeparvovec-xioi) spinal muscular atrophy (SMA) production - manufacturing Rare diseases - Neurodegenerative diseases - Neurological diseases Production agreement
2019-07-16 Servier (France) Pall (USA - NY) End-to-end solutions for Gidy biomanufacturing facility. services contract Services contract
2019-07-16 Alnylam Therapeutics (USA - MA) 23andMe (USA - CA) 23andMe Health + Ancestry kits transthyretin-mediated amyloidosis (ATTR) collaboration Rare diseases - Genetic diseases Collaboration agreement
2019-07-02 Amicus Therapeutics (USA - NJ) Paragon Gene Therapy, a unit of Catalent (USA - NJ) multiple active preclinical lysosomal disorder programs Pompe disease manufacturing - production Rare diseases - Genetic diseases Production agreement
2019-07-01 Amicus Therapeutics (USA - NJ) Brammer Bio, a part of Thermo Fisher Scientific (USA - MA) intrathecal AAV Batten disease gene therapy programs and other AAV  gene therapy programs Batten disease development - manufacturing - production Rare diseases - Genetic diseases - Neurological diseases - Technology - Services Production agreement
2019-06-26 3P Pharmaceuticals (Spain) Nordic Nanovector (Denmark) Betalutin™ (177Lu-tetraxetan-tetulomab) B-cell non-Hodgkin lymphoma (NHL) production - manufacturing Cancer - Oncology Production agreement
2019-06-24 Noxxon Pharma (Germany) undisclosedd top-10 pharmaceutical company NOX-A12 undisclosed undisclosed Licensing agreement
2019-06-21 Biomarin Pharmaceutical (USA - CA) Medivation (USA - CA), now Pfizer (USA - NY) talazoparib (BMN 673) metastatic breast cancer. product acquisition Cancer - Oncology Milestone
2019-06-20 Yposkesi (France) Axovant (Switzerland - USA) cGMP grade viral vector production development, manufacturing, production Rare diseases - Genetic diseases - Technology - Services Development agreement
2019-06-19 Gensight Biologics (France) member of the board of directors nomination Rare diseases - Genetic diseases - Ophtalmological diseases Nomination
2019-06-13 Amicus Therapeutics (USA - NJ) Senior Vice President of Discovery Research and Gene Therapy Science - Senior Vice President of International nomination Rare diseases - Genetic diseases Nomination
2019-06-06 3P Pharmaceutical (Spain) Affibody (Sweden) undisclosed recombinant protein undisclosed production - manufacturing Technology - Services Production agreement
2019-06-05 Yposkesi (France) Servier (France) lentiviral vectors manufacturing - production Technology - Services Production agreement
2019-05-29 Amicus Therapeutics (USA - NJ) University of Pennsylvania (USA - PA) AAV-based gene therapies Pompe disease, Fabry disease, CDKL5 deficiency disorder (CDD), Niemann-Pick Type C (NPC), mucopolysaccharidosis Type IIIB (MPS IIIB), mucopolysaccharidosis Type IIIA (MPS IIIA) R&D - research -development Rare diseases - Genetic diseases - Metabolic diseases Development agreement
2019-05-29 Alnylam Therapeutics (USA - MA) chief scientific officer(CSO) nomination Rare diseases - Genetic diseases Nomination
2019-05-29 Anchiano Therapeutics (USA - MA) head of business development nomination Cancer - Oncology Nomination